Canagliflozin - Another Top Longevity Drug

#2075

Oh come on, you have to pee an extra 5 times a day and a couple more at night with empag.

1 Like
#2076

Not true for me, but I may be in a specific situation insofar as I have always peed with a fairly high frequency, because I make sure to always drink a pretty high volume of liquids, so I doubt empaglifozin would necessarily increase the already high frequency.:person_shrugging:

#2077

Not for me either

#2078

Do they cite the Mendelian randomization showing increased lifespan in males and increased IQ?

If not then it’s a low-quality review.

2 Likes
#2079

I noticed no diuretic effect either - which may mean it isn’t really doing much.

If you notice a diuretic effect, isn’t that because you spike your sugars high and subsequently dump them. So everyone is going to be different.

And if you have a strong diuretic effect, definitely keep taking it and maybe up the acarbose or watch sugar intake.

3 Likes
#2080

There is no diuretic effect:

1 Like
#2081

Not for me either.

#2082

Has anyone read the paper? I’ve only been able to read the Abstract, which of course doesn’t mention Mendelian randomization.

1 Like
#2083

If it hasn’t already been posted - a short 16 minute talk at ARDD2025 about 8 short term studies experimenting with SGLT2i off-label in “normal” people (younger that 60, no diabetes, no CKD, no HF ):

This can produce valuable information, as there is the core argument, that SGLT2i are simply normalizing detrimental effects of diabetes/CKD.

4 Likes
#2084

Thanks for sharing. Gemini summary (bold mine):

  • Overview & Aim: The presentation discusses evaluating whether FDA-approved SGLT2 inhibitors (traditionally used for diabetes, kidney disease, and heart failure) can be repurposed as gerotherapeutics to optimize healthspan and lifespan in individuals without these diseases [03:30], [10:23].
  • Mechanism: SGLT2 inhibitors work by inhibiting glucose reabsorption in the kidneys, causing the body to excrete glucose through urine [03:44]. This pleiotropic drug lowers blood pressure and offers systemic metabolic and cardiac benefits [04:12].
  • Systematic Review Findings: A massive systematic review screened over 44,000 articles, ultimately analyzing 536 human studies [07:19].
  • Off-Label Data: Looking strictly at 8 completed trials involving younger, conventionally “healthy” cohorts (ages 30–60) taking the drug off-label, SGLT2 inhibitors showed highly positive, statistically significant improvements across multiple organ systems—specifically cardiovascular, metabolic, renal, hepatic, and adiposity systems [08:31], [09:49].
  • Research Gaps: Current off-label data severely lacks insights into how SGLT2i impacts the reproductive, immune, and nervous systems [10:51].
  • The HEARTS Trial: To fill these gaps, a multi-disciplinary, 6-month clinical trial is being launched in Singapore [11:53]. It will evaluate the effects of 10mg of daily SGLT2i on healthy individuals (ages 35–65) with an optimal BMI, focusing on VO2​ max as the primary outcome alongside digital and biological biomarkers [12:11].
6 Likes